Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27215111 | 1.00 | DGAT1 (0.38) | DGAT1NPC1HSD17B10PDE1BGSK3B | |
| SCHEMBL3300284 | 0.86 | DGAT1 (0.39) | DGAT1NPC1HSD17B10PDE1B | |
| SCHEMBL3373470 | 0.86 | GSK3B (0.35) | HSD17B10PDE1BGSK3B | |
| SCHEMBL19250755 | 0.85 | NPC1 (0.32) | DGAT1NPC1HSD17B10 | |
| SCHEMBL29900915 | 0.85 | DGAT1 (0.38) | DGAT1NPC1 | |
| SCHEMBL18673407 | 0.84 | HSD17B10 (0.31) | HSD17B10PDE1B | |
| SCHEMBL27193468 | 0.84 | DGAT1 (0.37) | DGAT1PDE1BGSK3B | |
| SCHEMBL24566116 | 0.83 | DGAT1 (0.37) | DGAT1PDE1BGSK3B | |
| SCHEMBL27193478 | 0.83 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL29705326 | 0.82 | DGAT1 (0.36) | DGAT1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026086812-A1 | INHIBITORS OF MENIN | RONGCHANG PHARMACEUTICALS, LTD. (CN) | 2026-04-30 | — | — | WO | disclosed |
| EP-4688778-A1 | 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Biogen MA Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | BIOLEXIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2024211696-A1 | 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN MA INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20240226115-A1 | AXL INHIBITOR COMPOUNDS | ARCUS BIOSCIENCES, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226115-A1 | AXL INHIBITOR COMPOUNDS | ARCUS BIOSCIENCES, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-117050072-B | Pyrazolopyridine derivative and application thereof | 沈阳药科大学 | 2024-05-17 | — | — | CN | disclosed |
| US-20240150345-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | PHARMARON UK LTD. (GB) | 2024-05-09 | — | — | US | disclosed |
| CN-117050072-A | Pyrazolopyridine derivative and application thereof | 沈阳药科大学 | 2023-11-14 | — | — | CN | disclosed |
| WO-2022246179-A1 | AXL INHIBITOR COMPOUNDS | ARCUS BIOSCIENCES, INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| WO-2008124848-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124848-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124850-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124850-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| EP-1778687-A2 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060035898-A1 | Fused ring heterocycle kinase modulators | STRUCTURAL GENOMIX, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| WO-2006015124-A2 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035898-A1 | Fused ring heterocycle kinase modulators | MAP3K20, TTK, MAP3K19 | DGAT1 3371/4885NPC1 3721/4885HSD17B10 2584/4885 |
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | PRKAB2, PRKAB1, PRKAR2B | DGAT1 3043/4885NPC1 1603/4885HSD17B10 4083/4885 |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, TTK, MAP3K19 | DGAT1 3371/4885NPC1 3721/4885HSD17B10 2584/4885 |
| US-20240150345-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | EIF2AK4, GCN1, CLN6 | DGAT1 565/4885NPC1 351/4885HSD17B10 1468/4885 |
| US-20240226115-A1 | AXL INHIBITOR COMPOUNDS | AXL, BTK, MERTK | DGAT1 3755/4885NPC1 3883/4885HSD17B10 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.